August 12, 2018 – Findings from a retrospective case-control study were published online August 8, 2018, in JAMA Dermatology indicate that the use of certain dipeptidyl peptidase 4 (DPP-4) inhibitor drugs are associated with a small but significantly elevated risk for developing bullous …

Risk of Bullous Pemphigoid with Type 2 Diabetes Drugs Read more »

Tagged with: , , , , , , , , , , , , ,

October 15, 2017 – According to the quarterly safety report April – June 2017 by the American Food & Drug Administration (FDA), originating from the  FDA Adverse Event Reporting System (FAERS), the class of diabetes drugs referred to as dipeptidyl peptidase-4 …

Diabetes: Is rhabdomyolysis associated with DPP-IV inhibitors? Read more »

Tagged with: , , , , , , , , , , , , , , , , , , , , , , , , ,